UBS analyst Peter Grom lowered the firm’s price target on Clorox (CLX) to $119 from $128 and keeps a Neutral rating on the shares. The firm has limited visibility on a second half inflection, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLX:
- Clorox Faces Continued Challenges with Declining Sales and Earnings: Hold Rating Affirmed
- Clorox price target lowered to $117 from $125 at Wells Fargo
- Clorox price target lowered to $120 from $130 at Citi
- Clorox Reports Q1 2026 Earnings Decline Amid ERP Transition
- Closing Bell Movers: Palantir down 3% after earnings